NDAORALTABLETPriority Review
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
CARAFATE (sucralfate) by AbbVie is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. First approved in 1981.
Drug data last refreshed 37m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARAFATE (sucralfate) is an oral aluminum complex indicated for duodenal ulcer treatment that works through local gastric action rather than systemic absorption. It forms an ulcer-adherent protective barrier, inhibits pepsin activity, and neutralizes acid at the ulcer site. The drug has been a cornerstone therapy since 1981 approval.
$0.002BPart D
LOE ApproachingDeclining
Late-lifecycle product with minimal Part D utilization (5,048 claims) signals a contracting brand team focused on defensive maintenance rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…
Pharmacologic Class:
Aluminum Complex
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CARAFATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.